View in EDS HTML Full Text PDF Full Text

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Saved in:
Bibliographic Details
Title: A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.
Authors: Mooradian, Meghan J.1,2, Reuben, Alexandre3, Prieto, Peter A.3, Hazar-Rethinam, Mehlika1,2, Frederick, Dennie T.1, Nadres, Brandon1,2, Piris, Adriano2,4, Juneja, Vikram5,6,7, Cooper, Zachary A.3, Sharpe, Arlene H.2,5,7, Corcoran, Ryan B.1,2, Flaherty, Keith T.1,2, Lawrence, Donald P.1,2, Wargo, Jennifer A.3, Sullivan, Ryan J.1,2,8 rsullivan7@partners.org
Source: OncoImmunology. 2018, Vol. 7 Issue 5, p1-1. 1p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21624011
DOI:10.1080/2162402X.2017.1423172